# Synergistic Effect of BRAF and TERT Mutations in Papillary Thyroid Carcinoma

The combination of a **BRAF V600E mutation** and a **TERT promoter mutation** defines a molecular subtype of Papillary Thyroid Carcinoma (PTC) with a particularly poor prognosis. The negative prognostic impact of these two mutations together is significantly greater than the sum of their individual effects.

### Clinical Implications
*   **High-Risk Profile:** This dual-mutation status is one of the strongest predictors of aggressive tumor behavior, recurrence, and disease-specific mortality.
*   **Recurrence Rates:** Patients with both mutations have markedly higher rates of recurrence. One meta-analysis reported a hazard ratio for recurrence of approximately **6.6** for dual-mutant tumors, compared to ~1.3 for BRAF-only mutants.
*   **Clinical Management:** Identifying this BRAF/TERT co-mutation may justify a more aggressive initial treatment strategy and a more intensive follow-up schedule due to the high risk of structural disease recurrence.

## Related Concepts
See also: [[Prognostic Significance of BRAF V600E in PTC]], [[TERT Promoter Mutation]], [[Papillary Thyroid Carcinoma]], [[Risk Stratification in Thyroid Cancer]]

## Tags
#prognosis #genetics #mutation #thyroid-cancer #PTC #high-risk
